![[Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19](/media/k2/items/cache/5ff2da698b3b76e8cdb9d0576e73d737_L.jpg)
[Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19
Press release: Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 Commentary: Eli Lilly’s combo therapy for COVID-19 cuts serious illness and death in large study – Reuters
The post [Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19 appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Non-inferiority RCT: Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended VTE Treatment
- Systematic Review: Shorter Antibiotic Courses Often Prove Non-Inferior for Common Bacterial Infections
- Network Meta-analysis: Oseltamivir Fails to Improve Key Outcomes in Nonsevere Influenza
- Multidrug-resistant Gram-negative bacterial infections: Key Updates and Practical Strategies
- Introducing Our Free WhatsApp Channels for Daily Internal Medicine Articles!